EQUASENS /Pharmagest – First-half 2022 revenue – 08/03/2022 at 6:00 p.m.


Growth of +10.3% to €103.57 million.

– On a like-for-like basis (excluding the acquisition of PROKOV EDITIONS), the Group recorded growth of +7.68% to €101.11 million.

Growth of all Divisions (with the exception of FINTECH, notably impacted by the economic situation).

Impacts of Ségur du Numérique in Health:

– The teams mobilized to submit the referencing files in accordance with the schedule imposed by the government program.

– The increase in turnover is more marked and dynamic in Q2 vs Q1: +11.48% vs +9.03%. The deployment of Ségur offers must be further intensified.

Confirmation of the Group’s business growth ambitions for 2022.

The entirety of this press release is online at www.equasens.com

Investors section / Press releases.

Listed on Euronext Paris™ – Compartment A

ISIN: FR0012882389 – Mnemonic code EQS



Source link -86